Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
CorrectionDEPARTMENTS

Erratum

Journal of Nuclear Medicine April 2003, 44 (4) 649;
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

There appears to be some ambiguity regarding the nomenclature of the lymphatic staining agents patent blue and isosulfan blue. The article “Why Certain Dyes Are Useful for Localizing the Sentinel Lymph Node,” by Tsopelas and Sutton (J Nucl Med. 2002;43:1377–1382), inadvertently linked these molecules, and other publications have interchanged these trade names (1,2) and mistaken Colour Index (CI) numbers (3) or Chemical Abstracts Service (CAS) registry numbers (4,5). The raw material patent blue is known by the synonyms sulphan blue, acid blue 1, patent blue VF, or food blue 3 and is defined by a CI number of 42045, a CAS number of 129-17-9, and a dye content of ∼50% (6). Based on the structure (7) in Figure 1A, its chemical name is N-[4-[[4-(diethylamino)phenyl]-(2,4-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium sodium salt or anhydro-4,4′-bis(diethylamino)-triphenylmethanol-2″,4″-disulphonic acid monosodium salt. Of the many listed synonyms of patent blue (8), one inclusion is patent blue V. Patent blue V has an alternative chemical structure that contains an additional hydroxyl functional group at position 5 (Fig. 1B) and is predominantly supplied as a calcium-chelated dimer. This compound is known as disulfine blue, acid blue 3, patent blue violet, or food blue 5 and has a CI number of 42051 and a CAS number of 3536-49-0, although no dye content is stated by a manufacturer (9). Based on the unchelated structure, its chemical name is N-[4-[[4-(diethylamino)phenyl]-(2,4-disulfo-5-hydroxyphenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium sodium salt or anhydro-4,4′-bis(diethylamino)-triphenylmethanol-5″-hydroxy-2″,4″-disulphonic acid monosodium salt. Isosulfan blue is a structural isomer of patent blue (Fig. 1C) in which the 2 sulfonic acid groups exist at the 2,5-positions of the phenyl ring (10). The proposed United States Adopted Name of this compound is isosulfan blue, and although no CI number has been assigned to it, there is a CAS number of 68238-36-8 and a dye content of 90% (2). The dyes in their pharmaceutical form are commercially available as contrast agents for visualizing lymphatic vessels. These products include bleu patente V sodique 2.5% w/v solution (Bleu Patenté V; Guerbet) in Australia and Europe, patent blue sodium injection 2.5% w/v solution (Therapex; E-Z-EM) in Canada, and isosulfan blue 1.0% w/v solution (Lymphazurin; U.S. Surgical/Tyco International) in the United States. When the names patent blue, patent blue V, and isosulfan blue have been used indiscriminately to describe the agent of choice, the authors suggest that reference to the dye employed should accurately reflect the correct chemical structure by confirmation with its distinct CAS number.

  FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Chemical structures of patent blue, CAS 129-17-9 (A); patent blue V, CAS 3536-49-0 (B); and isosulfan blue, CAS 68238-36-8 (C).

REFERENCES

  1. ↵
    Diagnostic agents. In: Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 31st ed. Suffolk, U.K.: William Clowes Ltd.; 1996:1106, 1108.
  2. ↵
    Biochemicals and Reagents for Life Science Research. St. Louis, MO: Sigma; 2001–2002:749.
  3. ↵
    Laboratory Chemicals. Seelze, Germany: Riedel-de-Haën; 1996:856.
  4. ↵
    Biochemicals and Reagents Catalog. Aurora, OH: ICN; 2000:527.
  5. ↵
    TCI Organic Chemicals Catalog. Portland, OR: TCI America; 2002–2003:37.
  6. ↵
    Handbook of Fine Chemicals and Laboratory Equipment. Milwaukee, WI: Aldrich; 2001–2002:1268.
  7. ↵
    Budavari S, ed. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. 12th ed. Whitehouse Station, NJ: Merck & Co. Inc.; 1996:1537.
  8. ↵
    International Agency for Research on Cancer (IARC): summaries and evaluations. Available at: http://www.inchem.org/pages/iarc.html. Accessed February 24, 2003.
  9. ↵
    Laboratory Chemicals and Analytical Reagents. Ronkonkoma, NY: Fluka; 1999–2000:1044.
  10. ↵
    Hirsch JI, Tisnado J, Cho SR, Beachley MC. Use of isosulfan blue for identification of lymphatic vessels: experimental and clinical evaluation. AJR. 1982;139:1061–1064.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 44, Issue 4
April 1, 2003
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Erratum
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Erratum
Journal of Nuclear Medicine Apr 2003, 44 (4) 649;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Erratum
Journal of Nuclear Medicine Apr 2003, 44 (4) 649;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Why Certain Dyes Are Useful for Localizing the Sentinel Lymph Node
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Recruitment
  • Recruitment
  • Recruitment
Show more Erratum

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire